# CAR-T cell therapy

> A figure of CAR-T cell therapy. The 3D model shows the chimeric antigen receptor — scFv through hinge, transmembrane domain and costimulation to CD3ζ — and a CAR-T cell killing a CD19⁺ leukaemic blast. Beside them, the five CAR generations module by module, and the manufacturing route from leukapheresis to infusion. Architecture as in June et al. 2018.

- Page: https://www.labcanvas.com/templates/cancer-biology/car-t-cell-therapy
- Open in the LabCanvas editor (LabCanvas account): https://www.labcanvas.com/editor.html?template=car-t-cell-therapy
- Updated: 2026-10-14
- Category: Cancer biology
- Method: Graphical abstract
- Product: A patient’s T cells re-engineered to recognise and kill a tumour antigen
- Key result: CD19 CAR-T cells treat B-cell leukaemia and lymphoma (Maude 2018); BCMA CAR-T cells treat myeloma (Raje 2019); cytokine release syndrome and ICANS are the key toxicities (Morris 2022)
- Figure: 1920 × 1080 px, 104 editable layers (6 generated objects with settings)

## Steps

1. **The receptor**: An scFv antigen-binding head on a hinge and transmembrane domain, a costimulatory domain (CD28 or 4-1BB) and the CD3ζ signalling tail (Sadelain 2013)
2. **Five generations**: 1st CD3ζ alone; 2nd adds one costimulatory domain; 3rd adds two; 4th (TRUCK) adds an inducible cytokine; 5th adds an IL-2Rβ fragment (June et al. 2018)
3. **Killing**: The CAR-T cell forms a synapse on a CD19⁺ or BCMA⁺ target, delivers perforin and granzymes and releases cytokines (June et al. 2018)
4. **Manufacturing**: Leukapheresis, T-cell activation, lentiviral transduction, expansion, lymphodepletion and infusion (June et al. 2018)

## Uses

- Immunotherapy review and graphical-abstract figures
- Talks on cell therapy and CAR design
- Teaching the CAR generations and manufacturing

## References

1. June et al., “CAR T cell immunotherapy for human cancer”, Science 2018. https://doi.org/10.1126/science.aar6711 (review)
2. Sadelain, Brentjens & Rivière, “The basic principles of chimeric antigen receptor design”, Cancer Discov. 2013. https://doi.org/10.1158/2159-8290.CD-12-0548 (primary)
3. Maude et al., “Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia”, N. Engl. J. Med. 2018. https://doi.org/10.1056/NEJMoa1709866 (primary)
4. Raje et al., “Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma”, N. Engl. J. Med. 2019. https://doi.org/10.1056/NEJMoa1817226 (primary)
5. Morris et al., “Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy”, Nat. Rev. Immunol. 2022. https://doi.org/10.1038/s41577-021-00547-6 (review)

Credit: Drawn in LabCanvas after June et al., Science 2018 (doi:10.1126/science.aar6711); Sadelain, Brentjens & Rivière, Cancer Discov. 2013 (doi:10.1158/2159-8290.CD-12-0548); Maude et al., NEJM 2018 (doi:10.1056/NEJMoa1709866); Raje et al., NEJM 2019 (doi:10.1056/NEJMoa1817226); and Morris et al., Nat. Rev. Immunol. 2022 (doi:10.1038/s41577-021-00547-6). Domains enlarged to read; schematic.

## Questions

**What does the “CAR-T cell therapy” template show?** A figure of CAR-T cell therapy. The 3D model shows the chimeric antigen receptor — scFv through hinge, transmembrane domain and costimulation to CD3ζ — and a CAR-T cell killing a CD19⁺ leukaemic blast. Beside them, the five CAR generations module by module, and the manufacturing route from leukapheresis to infusion. Architecture as in June et al. 2018.

**What are the steps shown in “CAR-T cell therapy”?** 1. The receptor: An scFv antigen-binding head on a hinge and transmembrane domain, a costimulatory domain (CD28 or 4-1BB) and the CD3ζ signalling tail (Sadelain 2013). 2. Five generations: 1st CD3ζ alone; 2nd adds one costimulatory domain; 3rd adds two; 4th (TRUCK) adds an inducible cytokine; 5th adds an IL-2Rβ fragment (June et al. 2018). 3. Killing: The CAR-T cell forms a synapse on a CD19⁺ or BCMA⁺ target, delivers perforin and granzymes and releases cytokines (June et al. 2018). 4. Manufacturing: Leukapheresis, T-cell activation, lentiviral transduction, expansion, lymphodepletion and infusion (June et al. 2018).

**Which papers is “CAR-T cell therapy” based on?** June et al., “CAR T cell immunotherapy for human cancer”, Science 2018 (doi:10.1126/science.aar6711); Sadelain, Brentjens & Rivière, “The basic principles of chimeric antigen receptor design”, Cancer Discov. 2013 (doi:10.1158/2159-8290.CD-12-0548); Maude et al., “Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia”, N. Engl. J. Med. 2018 (doi:10.1056/NEJMoa1709866); Raje et al., “Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma”, N. Engl. J. Med. 2019 (doi:10.1056/NEJMoa1817226); Morris et al., “Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy”, Nat. Rev. Immunol. 2022 (doi:10.1038/s41577-021-00547-6).

**Can I edit the “CAR-T cell therapy” template?** Yes. Open it in the LabCanvas editor: all 104 layers are editable, including 6 generated objects (structures, plots, equipment) with their own settings. Change the text, colours and layout, then export PNG, TIFF or PDF at the width and DPI the journal asks for.

**Do I need an account to use this template?** Not to view it here. To open and edit it, sign in to LabCanvas or create a free account (the free plan keeps up to 3 designs). Downloading the figure is part of LabCanvas Pro (US$19 a month or US$199 a year).
